Market Signal Briefing

TLDR

Upexi has appointed SOL Big Brain, a Solana investor, to its advisory committee.
The company now has Arthur Hayes, co-founder of BitMEX, on its advisory team.
Upexi’s Solana strategy includes holding over 2 million SOL tokens, valued at approximately $410 million.
The company stakes most of its Solana holdings to earn an 8% yield for investors.
Upexi’s net asset value has increased to $433 million, thanks to Solana’s rising market price.

Upexi, the Nasdaq-listed company, has named prominent Solana investor SOL Big Brain to its advisory committee. The move, announced Tuesday, aims to strengthen the company’s crypto strategy. SOL Big Brain joins Maelstrom Fund co-founder Arthur Hayes, who was appointed earlier this year.

Upexi’s Solana Strategy Grows Stronger
Upexi has increasingly focused on Solana, after shifting from its origins as a consumer brand aggregator. In April, the company began its large-scale accumulation of Solana’s SOL tokens with a $6.7 million purchase. It now holds over 2 million SOL tokens, valued at around $410 million.

The company states that it stakes most of its Solana holdings to earn about an 8% yield. By doing so, Upexi offers investors institutional-grade exposure to Solana without requiring them to manage infrastructure. This approach aligns with Upexi’s broader strategy to leverage cryptocurrency for growth while maintaining simplicity.

Key Figures in Upexi’s Crypto Leadership
Upexi’s advisory committee now includes two well-known figures from the crypto world. SOL Big Brain, a prominent Solana investor, brings significant expertise to the team. Hayes, a former BitMEX co-founder, brings his experience from aggressively trading memecoins like PEPE.

Hayes has shifted his focus toward high-yield decentralized finance (DeFi) protocols, such as EtherFi and Ethena. He believes that the next wave of crypto growth will come from projects that reward tokenholders with shared revenue. His insights further strengthen Upexi’s strategic positioning within the crypto space.

Upexi’s Solana bet has been advantageous, particularly with the rise in SOL’s market price. When the company started accumulating SOL, it was priced around $100, near a 13-month low. Since then, the price has more than doubled to $208, boosting Upexi’s net asset value to $433 million.

Shiba Inu is down 1.83% in its trading price over the last 24 hours. However, a relative decline in its exchange net inflow has triggered attention from investors.

According to data from an on-chain analytics platform, Shiba Inu has recorded a decrease of 154.4 billion SHIB in its overall net inflow across all supported exchanges, including Coinbase, Binance, and others.

SHIB holders show resilience Despite the slowdown in Shiba Inu’s trading price, its exchange flows have shown a 21.83% decline, suggesting that holders have shown less interest in selling.

HOT Stories

While this key metric signals a dramatic shift in investor sentiment, it appears that the decline in SHIB’s trading price is not entirely attributed to speculative trading. Rather, it might be the leading altcoin responding to the broader market trend.

The metric, which marks the difference between exchange inflows and outflows, suggests that the amount of Shiba Inu tokens withdrawn from exchanges is larger than the amount of tokens deposited for sale by 154,448,000,000 SHIB.

This trend indicates that many small and large SHIB holders have shown no interest in selling their holdings despite the negative price trend. Instead, they are moving their tokens into self-custody wallets to hold for longer periods.

While the decline in exchange flows stands as a bullish indicator, it aims to tighten the supply available on crypto exchanges while propelling the token toward a potential price upsurge.

Although the low selling activity could highlight strong investor confidence, it is also important to note that the slow market activity could mean that investors are trading with caution.

The sharp plunge in net flows could help stabilize the price movements of the leading memecoin, and investors are confident that the token might be set for bigger price rallies ahead.

To further build momentum for the dog-themed meme cryptocurrency, its burn activity has also surged decently by 22.98% after staying flat in previous days.

With 171,407 SHIB tokens moved out of circulation today, the resurgence in the SHIB burn rate aligns with the decline in exchange net flows, as they work hand in hand to tighten the SHIB supply while driving demand for the token.

TLDR

Michael Saylor revealed that Strategy aims to accumulate $1 trillion in Bitcoin for its treasury.
Saylor believes Bitcoin represents a revolutionary form of energy, capital, and property in cyberspace.
Strategy’s Bitcoin strategy has inspired over 180 publicly traded companies to adopt Bitcoin as a core treasury asset.
Saylor predicts that major companies like Apple, Google, and Microsoft will eventually embed Bitcoin support into their systems.
He dismissed concerns about corporate investors crowding out individual investors, citing significant gains for retail holders.

Michael Saylor, the executive chairman of Strategy, has outlined an ambitious plan to accumulate $1 trillion in Bitcoin. Saylor believes Bitcoin represents a new form of energy and capital, comparing it to transformative forces like fire, electricity, and oil. According to Saylor, the end goal for Strategy is to hold a trillion dollars’ worth of Bitcoin and expand its influence from there.

Saylor sees Bitcoin as a revolutionary force in digital energy, offering a unique way to transfer value. He views it as property, capital, and energy in cyberspace, transcending traditional forms of wealth. Saylor’s vision is for Bitcoin to become a core asset for both corporations and individuals in the digital age.

Bitcoin as a Paradigm Shift in Corporate Strategy
Saylor highlighted the growing importance of Bitcoin within corporate strategies. Since 2020, Strategy has led the charge in adopting Bitcoin as a treasury asset, inspiring numerous other companies to follow suit. He predicts that over 180 publicly traded companies already hold Bitcoin, and the number will rise into the thousands in the coming years.

As more companies adopt Bitcoin, Saylor expects major firms like Apple, Google, and Microsoft to integrate Bitcoin support into their operating systems and hardware. He believes that such moves will signal widespread mainstream adoption. Saylor’s bold prediction is that Bitcoin will outperform the S&P 500 indefinitely, changing the financial landscape.

Saylor Believes Bitcoin Growth Benefits All Investors
Saylor is confident that Bitcoin’s growth will benefit both corporations and individual investors. He rejected concerns that corporate investments in Bitcoin would crowd out retail investors. In fact, he pointed out that individual investors have seen significant gains since corporations like Strategy began accumulating Bitcoin.

Strategy’s strategy of acquiring more Bitcoin has not only boosted the company’s performance but also strengthened the entire Bitcoin network. According to Saylor, corporate adoption of Bitcoin is a net positive for early investors. He emphasized that Bitcoin’s decentralized nature ensures that individuals, companies, and even governments can hold their own reserves without relying on central institutions.

Saylor’s vision for Bitcoin extends beyond corporate success. He views it as a global system of trust and economic integrity. For him, the trillion-dollar goal is a step toward a new foundation of digital energy and value.

September 30, 2025 17:01 ET

 | Source:

Carlyle Secured Lending, Inc.

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (Nasdaq: CGBD) (the “Company”) today announced that it has priced an underwritten public offering of $300 million in aggregate principal amount of 5.750% unsecured notes due 2031 (the “Notes”). The Notes will mature on February 15, 2031 and may be redeemed in whole or in part at the Company’s option at the applicable redemption price. The offering is expected to close on October 7, 2025, subject to customary closing conditions.

The Company intends to use the net proceeds from this offering to repay outstanding debt including the Company’s revolving credit facility (which the Company intends to use to repay its subsidiary’s revolving credit facility), to fund new investment opportunities, and for other general corporate purposes, which may include opportunistic repurchases of outstanding debt.

J.P. Morgan Securities LLC, Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, HSBC Securities (USA) Inc., and R. Seelaus & Co., LLC are acting as joint book-running managers for this offering. ICBC Standard Bank Plc, B. Riley Securities, Inc., Citizens JMP Securities, LLC, Keefe, Bruyette & Woods, Inc., Lucid Capital Markets, LLC, Oppenheimer & Co. Inc., and Raymond James & Associates, Inc. are acting as co-managers for this offering.

Investors are advised to carefully consider the investment objectives, risks and charges and expenses of the Company before investing. The pricing term sheet dated September 30, 2025, preliminary prospectus supplement, dated September 30, 2025, and the accompanying prospectus, dated April 29, 2024, each of which has been filed with the U.S. Securities and Exchange Commission (the “SEC”), contain a description of these matters and other information about the Company and should be read carefully before investing.

The Company’s shelf registration statement is on file with the SEC and is effective. The offering is being made solely by means of a preliminary prospectus supplement and an accompanying prospectus, which may be obtained for free by visiting the SEC’s website at www.sec.gov or by contacting J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, Attn: Investment Grade Syndicate Desk, facsimile: 212-834-6081 or by calling at 1-212-834-4533; Barclays Capital Inc., 745 Seventh Avenue, New York, New York 10019, Attention: Syndicate Registration, facsimile: 646-834-8133 or by calling at 1-888-603-5847; BofA Securities, Inc.,NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attn: Prospectus Department, email: [email protected] or by calling toll-free at 1-800-294-1322; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Telephone: (800) 831-9146, email: [email protected]; Deutsche Bank Securities Inc., 1 Columbus Circle, New York, New York 10019, Attention: Debt Capital Markets Syndicate, email: [email protected] or by calling at 1-800-503-4611; or Morgan Stanley & Co. LLC, 1585 Broadway, 29th Floor, New York, New York 10036, Attn: Investment Banking Division, facsimile: 203-719-0495 or by calling toll-free at 1-866-718-1649.

The information in the pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus and this press release is not complete and may change. The pricing term sheet, the preliminary prospectus supplement, the accompanying prospectus, and this press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Carlyle Secured Lending: Carlyle Secured Lending, Inc. is a closed-end, non-diversified and externally managed investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended. Our objective is to generate current income and capital appreciation by sourcing and providing senior secured debt investments to U.S. companies in the middle market that are generally backed by private equity sponsors. The Company is managed by Carlyle Global Credit Investment Management L.L.C., an SEC-registered investment adviser and a wholly owned subsidiary of Carlyle. We derive significant benefit from our ability access and leverage Carlyle’s significant scale, vast resources and world-class talent.

About Carlyle: Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Carlyle AlpInvest. With $465 billion of assets under management as of June 30, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,300 people in 27 offices across four continents.

Forward-Looking Statements

Statements included herein contain certain “forward-looking statements” within the meaning of the federal securities laws, including statements with regard to the Company’s Notes offering and the anticipated use of the net proceeds of the offering. You can identify these statements by the use of forward-looking terminology such as “anticipates,” “believes,” “expects,” “intends,” “will,” “should,” “may,” “plans,” “continue,” “believes,” “seeks,” “estimates,” “would,” “could,” “targets,” “projects,” “outlook,” “potential,” “predicts” and variations of these words and similar expressions to identify forward-looking statements, although not all forward-looking statements include these words. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. You should not place undue reliance on these forward-looking statements, which speak only as of the date on which we make it. Factors or events that could cause our actual results to differ, possibly materially from our expectations, include, but are not limited to, the risks, uncertainties and other factors we identify in the sections entitled “Risk Factors,” “Supplementary Risk Factors” and “Special Note Regarding Forward-Looking Statements” in filings we make with the SEC, and it is not possible for us to predict or identify all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:   Investors: Media:Nishil MehtaKristen Ashton+1 (212) 813-4918+1 (212) [email protected]@carlyle.com
SOURCE: Carlyle Secured Lending, Inc.

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against V.F. Corporation ("VF" or "the Company") (NYSE: VFC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 30, 2023 and May 20, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before November 12, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. VF promised investors its revenue outlook was reliable and minimized the risk of seasonality and macroeconomic fluctuations. The Company's positivity on growth as well as cost-cutting measures had no basis in reality. Based on these facts, the Company's public statements were false and materially misleading. When the market learned the truth about VF, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

SAN FRANCISCO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) saw the price of their shares crater $55.75, or about 90%, after the company announced disastrous VELA-2 trial results for sonelokimab, its highly anticipated treatment for patients with skin disease (hidradenitis suppurative or “HS”).

The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether MoonLake may have misled investors about sonelokimab’s trial design and efficacy.

The firm urges investors in MoonLake who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

Visit: www.hbsslaw.com/investor-fraud/mltx
Contact the Firm Now: [email protected]
                                                844-916-0895

MoonLake Immunotherapeutics (MLTX) Investigation:

The investigation is focused on MoonLake’s disclosures about the company’s planning for possible intercurrent events after participants start treatment and about the likelihood of achieving the HiSCR75 primary endpoint - a scale which defines treatment success as at least a 75% reduction in inflammatory lesions.

Before Sept. 29, 2025, MoonLake expressed confidence to investors in sonelokimab’s trial designs, encouraged the belief that the studies could show at least a 20% difference between the sonelokimab group and patients given a placebo, and has assured investors that “we really have a drug here that can become the gold standard and obviously that will facilitate any winning that we do with sonelokimab in HS.”

Investors’ expectations were dashed on Sep. 29, 2025, when MoonLake announced that in its VELA-2 trial “intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy (HiSCR75, delta to placebo of 9%[.]”

On this news, the price of MoonLake shares cratered $55.75 (-90%) that day, with one analyst reportedly writing in a note to investors that the results “’arguably fall[] into the worst case outcome.’”

“We’re focused on investors’ losses and whether MoonLake may have misled investors about the VELA-2 design and planning for potential intercurrent events while claiming that sonelokimab could become a ‘gold standard’,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in MoonLake and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the MoonLake investigation, read more »

Whistleblowers: Persons with non-public information regarding MoonLake should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Contact:
Reed Kathrein, 844-916-0895

NEW YORK , Sept. 30, 2025 /PRNewswire/ -- Omnicom Group Inc. ("Omnicom") (NYSE: OMC) and The Interpublic Group of Companies, Inc. ("IPG") (NYSE: IPG) today announced that the regulatory approval process for Omnicom's pending acquisition of IPG continues and has been completed in all required jurisdictions other than Mexico and the European Union.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Lantheus (LNTH) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Lantheus securities between February 26, 2025, to August 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ:LNTH) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired securities between February 26, 2025, to August 5, 2025, both dates inclusive (the “Class Period”).Investors have until November 10th, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Defendants provided overwhelmingly positive statements to investors while concealing material adverse facts concerning the true state of Pylarify's competitive position; (2) Lantheus was not equipped to properly assess the pricing and competitive dynamics for Pylarify; (3) the Company failed to disclose that its early 2025 price increase-issued despite prior price erosion-created an opportunity for competitive pricing to flourish, thereby jeopardizing Pylarify's price point, revenue, and overall growth potential; and (4) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading at all relevant times.
Next Steps:

If you purchased or otherwise acquired Lantheus shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Align (ALGN) To Contact Him Directly To Discuss Their Options

If you purchased or acquired stock in Align and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Align Technology, Inc. (“Align” or the “Company”) (NASDAQ:ALGN) on behalf of Align stockholders. Our investigation concerns whether Align has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details:

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Align announced its Q2 2025 financial results on July 30, 2025. The Company missed both analyst expectations and its own guidance on revenue. The Company lowered its Q3 revenue guidance and full year growth expectations. Based on these facts, the Company’s shares dropped by almost 37% on the next day. Next Steps:

If you purchased or otherwise acquired Align shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Hudson Tunnel Project Proves that America is Building Again

, /PRNewswire/ -- MPA Delivery Partners, the joint venture of Mace, Parsons Corporation (NYSE: PSN), and Arcadis (AMS: ARCAD) announced today that the team has been awarded a $665 million, 4.5-year contract extension by the Gateway Development Commission (GDC) to continue managing the successful delivery of the Hudson Tunnel Project (HTP).

The HTP is progressing on-schedule and expected to create more than 95,000 jobs around the United States and generate more than $19 billion in economic activity. In addition to the thousands of talented employees in the New York/New Jersey region, the project is driving demand for U.S. suppliers of steel, aggregates, rail and track, and ventilation systems. Companies from North Carolina, Texas, Pennsylvania, Ohio, Alabama, Colorado, and Tennessee are benefiting from the Hudson Tunnel Project, unlocking the power of American ingenuity, and proving that the country is building again. With multiple active construction sites managing different portions of the HTP, the project is on-schedule for the new Gateway Tunnel completion in 2035, and the existing tunnel's rehabilitation by 2038.

"This is a once-in-a-generation project and a true collaboration between the public and private sectors that will serve as a model for delivering future mega-infrastructure projects around the world," said Joe Marie, senior project executive for MPA Delivery Partners. "We are united in our goal of successfully completing this critical project, which will transform the Northeast Corridor and deliver billions of dollars of economic growth to the U.S. economy. GDC and MPA function as a fully integrated partnership, working closely together to ensure the Hudson Tunnel Project is completed on time and within budget."

The Hudson Tunnel Project is the cornerstone of the Gateway Program and is widely considered the most urgent rail infrastructure project in the United States. The transformational project involves building a brand new two-tube rail tunnel under the Hudson River and rehabilitating the existing 115-year-old tunnel as well as nine miles of new passenger rail track between New York and New Jersey to improve passenger rail service and enhance the reliability of the Northeast Corridor. These improvements will accelerate economic prosperity and growth around the country while improving long-term reliability and redundancy of the regional and national rail networks for NJ TRANSIT and Amtrak. Ultimately, the Hudson Tunnel Project will establish a new 100-year legacy of engineering excellence built by and for America.

MPA was selected as the delivery partner on the project in February 2024. The delivery partner model has an internationally proven track record for helping public agencies deliver large-scale infrastructure projects. The collaborative delivery partner model has an internationally proven success record for helping public- and private-sector organizations deliver large-scale capital projects with benchmark efficiency and socioeconomic benefits.

About Mace

Mace Consult  is the leading global consultancy fully focused on program  management and delivery across property and infrastructure sectors—from mobility to commercial property, data centers, advanced science and industrial facilities, and sports and entertainment venues on the world stage. Mace founded the collaborative delivery partner model proven by successful mega programs including the London 2012 Olympics, Dubai Expo 2020, and Metrolinx GO and Subways programs in Toronto. For 30 years, it has set the industry standard for world-class project management; PMO (program management office) and controls; cost and commercial management; and advisory services ranging from capital planning, to sustainable business and digital transformation.

The news follows the announcement in July 2025 of a majority investment in Mace Consult by Goldman Sachs Alternatives to establish the consulting business as an independent company. The transaction is subject to regulatory approvals (amongst other conditions) and is expected to close in 2025.

SOURCE Mace Group

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against V.F. Corporation ("VF " or "the Company") (NYSE: VFC ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of VFC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: October 30, 2023 to May 20, 2025

DEADLINE: November 12, 2025

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. VF minimized the risk of seasonality and other risks in its communications to investors. The Company also claimed it could reliably forecast its revenue. In fact, the Company's positive outlook on revenue growth was not based on reliable data. Based on these facts, VF's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

NEXT STEPS FOR SHAREHOLDERS : Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT: 
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]

SOURCE DJS Law Group LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Draganfly Today

$8.14 +1.19 (+17.12%)

As of 04:00 PM Eastern

52-Week Range$1.63▼

$9.55Price Target$6.50

On Sept. 30, the market delivered a powerful and unambiguous verdict on Draganfly Inc. NASDAQ: DPRO. Shares of the drone technology company surged over 17%, driven by an unprecedented wave of investor interest that saw trading volume skyrocket to more than 58 million shares, a staggering figure compared to its daily average of roughly 1.9 million shares. This dramatic market action was ignited by a single, transformative catalyst: the announcement of a multifaceted contract with the U.S. Army.

For investors scrutinizing the company, this event signifies far more than a short-term price spike; it represents the culmination of a focused strategic pivot, potentially launching Draganfly into a new and far more stable phase of growth.

Get Draganfly alerts:

The Army Partnership: A Pillar of Growth
The agreement with the U.S. Army is significant not just for its prestige, but for its intelligent and deeply integrated structure. This contract provides Draganfly with more than a one-time hardware sale. It is a foundational partnership designed for long-term operational readiness, a distinction that fundamentally changes how investors should assess the company's future revenue potential and competitive standing.

More Than Drones: Strategic Depth
The contract's design reveals a forward-thinking approach that creates a durable and defensible relationship. It is built on three core pillars:

Advanced Technology: Draganfly will supply its high-performance Flex FPV (First Person View) drone systems. FPV technology, which gives operators a real-time, in-the-field view from the drone's perspective, has proven to be a game-changer for reconnaissance and tactical missions in modern conflicts, making it a high-priority capability for the U.S. military.
Embedded Manufacturing: As a key strategic differentiator, Draganfly will help establish on-site drone manufacturing within U.S. military facilities overseas. This innovative model is a logistical masterstroke, shortening critical supply chains, accelerating deployment, and embedding Draganfly's processes and technology directly into Army operations.
Training and Support: The company will also provide comprehensive flight and manufacturing training to Army personnel. This creates an ongoing service and support component, ensuring the U.S. Army can sustain its own drone operations and cementing Draganfly's role as an indispensable partner, not just a vendor.

From Plan to Partnership: A Proven Strategy
This landmark contract was the direct result of a series of deliberate strategic moves that validated Draganfly's technology and aligned the company with the stringent requirements of the Department of Defense (DoD). The company’s successful technology demonstrations at the T-REX 24-2 military exercise in September served as a crucial proof of concept.

The win was further enabled by Draganfly's proactive expansion of its U.S. manufacturing footprint and its steadfast focus on building a secure, NDAA-compliant supply chain, a non-negotiable prerequisite for sensitive defense contracts that immediately disqualifies many foreign-based competitors. The contract is the culmination of a clear pattern of execution by management, building on other key partnerships in the defense and humanitarian sectors, such as Draganfly’s work with SafeLane Global on demining drones.

Fuel for Growth: A Strong Balance Sheet
A major contract win can strain a smaller company's resources, but Draganfly's financial planning appears to have positioned it well to execute. While the company is still in its growth phase, it reported a net loss of $4.7 million in its second quarter 2025 earnings report; however, its balance sheet shows considerable strength.

At the end of Q2 2025, Draganfly's cash balance exceeded $22.5 million. This was further strengthened by a $25 million registered direct offering that was finalized in July. This capital base is critical, providing the necessary fuel to scale production and manage the complex logistics of the U.S. Army contract without the immediate need for dilutive financing. It allows the company to confidently fund its operations and bridge the gap toward what could be a significant and sustained increase in revenue.

A New Baseline for Draganfly’s Valuation
Draganfly Stock Forecast Today12-Month Stock Price Forecast:
$6.50
-20.15% Downside

Buy
Based on 2 Analyst Ratings

Current Price$8.14High Forecast$7.00Average Forecast$6.50Low Forecast$6.00Draganfly Stock Forecast Details

The partnership with the U.S. Army fundamentally alters the investment narrative for Draganfly. This contract serves as a powerful validation, effectively de-risking the company's technology and business model in the eyes of the market. It demonstrates a clear ability to move beyond smaller-scale programs and secure a cornerstone contract with one of the world's most demanding clients.

Consequently, prior analyst valuations and price targets, which currently form the consensus average of $6.50, are now based on outdated information. These figures were established before this transformative agreement was announced and are likely subject to upward revisions as financial models are updated to reflect this new reality. 

For investors, the conversation has shifted. The question is no longer whether Draganfly can win in the competitive defense sector but rather how effectively it can execute this foundational contract and leverage it to secure future growth. This U.S. Army deal establishes a new, and significantly higher, baseline for Draganfly’s trajectory and potential valuation.

Should You Invest $1,000 in Draganfly Right Now?Before you consider Draganfly, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Draganfly wasn't on the list.

While Draganfly currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

EON Resources Inc. (NYSE:EONR) Special Conference Call

Company Participants

Michael J. Porter - Investor Relations
Dante Caravaggio - President, CEO & Director
David M. Smith, Esq. - General Counsel
Mitchell Trotter - CFO, Senior VP & Director
Jesse Allen - Vice President of Operation
David Smith - VP, General Counsel & Secretary

Presentation

Operator

Good day, everyone, and welcome to the EON Resources, Inc. Special Conference Call discussion of $45.5 million funding and related Farmout Agreement. [Operator Instructions]. It is now my pleasure to turn the floor over to your host, Michael Porter. Sir, the floor is yours.

Michael J. Porter

Thank you, Matthew. Good afternoon, ladies and gentlemen, and welcome to our Special Conference Call. Before I turn the call over to management, I have to read the forward-looking statements.

This conference call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as expect, believe, anticipate, seek, might, plan, any variation in similar words and expressions are intended to identify such forward-looking statements. But in the absence of these words, it does not mean that a statement is not forward-looking. The company expectations are disclosed in the company's documents filed from time to time on EDGAR and with the Securities and Exchange Commission.

Without further ado, I'd like to turn the call over to Dante. Dante, the floor is yours.

Dante Caravaggio
President, CEO & Director

Thank you, Mike. Good afternoon, everybody. We're getting to be old friends. This is probably the seventh or eighth, one of these things we've done as a group. I apologize upfront because I'm in an airport, and we're going to get a little bit of background noise. So I'm on company overview slide. And all I'm going to highlight there is -- all

Recommended For You

SAXONBURG, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, proudly announced today that it has been recognized with two awards at ECOC 2025, Europe’s largest optical communications exhibition. The honors highlight Coherent’s commitment to driving breakthrough technologies that are enabling the next generation of high-performance, AI networks.

The following Coherent products were recognized for their innovation in their respective categories:

Optical Transport Award: Multi-Rail Resource Pooling System
An advanced optical amplification architecture that pools dynamic gain equalizers, channel monitors, and pump lasers across multiple transmission paths to boost C- and L-band throughput while cutting power, space, and hardware requirements.

Most Innovative Photonic Component Award: 400G Differential EML
The industry’s first 400G D-EML, offering >100 GHz bandwidth, low reflections, and reduced power consumption for cost-effective, scalable optical transceivers.

“We are honored to receive industry recognition at ECOC 2025, which reinforces Coherent’s position as a leader in optical innovation,” said Dr. Julie Eng, Chief Technology Officer at Coherent. “These achievements reflect the extraordinary expertise of our global teams and our ongoing commitment to deliver scalable, reliable, and energy-efficient technologies that power the future of communications.”

Coherent’s award-winning portfolio showcases the company’s unmatched breadth across materials, components, and systems. By driving innovation in optical communications, Coherent is helping customers address the unprecedented growth in datacenter, AI, and telecom networks.

About Coherent 

Coherent is the global photonics leader. We harness photons to drive innovation. Industry leaders in the datacenter, communications, and industrial markets rely on Coherent’s world-leading technology to fuel their own innovation and growth.

Founded in 1971 and operating in more than 20 countries, Coherent brings the industry’s broadest, deepest technology stack; unmatched supply chain resilience; and global scale to help its customers solve their toughest technology challenges. Visit us at coherent.com.

Media Contact: 
[email protected] 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0978af78-9424-4253-af22-60bd6e7d0c01

Coherent honored at ECOC 2025
Coherent honored at ECOC 2025 with Industry Recognition for Optical Innovation

NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities (as well as purchasers of call options or sellers of put options) of Charter Communications, Inc. (NASDAQ: CHTR) between July 26, 2024 and July 24, 2025, both dates inclusive (the “Class Period”), of the important October 13, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Charter Communications securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Charter Communications class action, go to https://rosenlegal.com/submit-form/?case_id=44682 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the impact of the Federal Communications Commission’s (“FCC”) Affordable Connectivity Program (“ACP”) end was a material event the Company was unable to manage or promptly move beyond; (2) the ACP end was having a sustaining impact on Internet customer declines and revenue; (3) neither was Charter Communications executing broader operations in a way that would compensate for, or overcome the impact, of the ACP ending; (4) the Internet customer declines and broader failure of Charter’s execution strategy created much greater risks on business plans and earnings growth than reported; (5) accordingly, Charter Communications had no reasonable basis to state that it was successfully executing operations, managing causes of Internet customer declines, or provide overly optimistic statements about the long term trajectory of the Company and EBITDA growth; and (6) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements about Charter Communications’ business, operations, outlook during the Class Period. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Charter Communications class action, go to https://rosenlegal.com/submit-form/?case_id=44682 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Proceeds from the offering of senior unsecured notes, together with cash on hand, to be used to redeem $2.0 billion of 6.000% senior unsecured notes due 2029

, /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) today announced that Carnival Corporation (the "Company") priced its private offering (the "Notes Offering") of $1.25 billion aggregate principal amount of 5.125% senior unsecured notes due 2029 (the "Notes").

The Company expects to use the proceeds from the Notes Offering, together with cash on hand, to redeem its $2.0 billion 6.000% senior unsecured notes due 2029 (the "2029 Unsecured Notes") after the closing of the Notes Offering.

The transaction is a continuation of the Company's strategy to reduce interest expense. In addition, the indenture that will govern the Notes will have investment grade-style covenants.

The Notes Offering is expected to close on October 15, 2025, subject to customary closing conditions.

The Notes will pay interest semi-annually on May 1 and November 1 of each year, beginning on May 1, 2026 at a rate of 5.125% per year. The Notes will be unsecured and will mature on May 1, 2029. The Notes will be fully and unconditionally guaranteed on an unsecured basis, jointly and severally, by Carnival plc and certain of the Company's and Carnival plc's subsidiaries that also guarantee our first-priority secured indebtedness, certain of our other unsecured notes and our convertible notes.

This press release does not constitute a notice of redemption with respect to the 2029 Unsecured Notes.

The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and outside the United States, only to non-U.S. investors pursuant to Regulation S under the Securities Act.

The Notes will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to purchase the Notes or any other securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offering, solicitation or sale would be unlawful.

About Carnival Corporation & plc

Carnival Corporation & plc is the largest global cruise company, and among the largest leisure travel companies, with a portfolio of world-class cruise lines - AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, P&O Cruises, Princess Cruises and Seabourn.

Cautionary Note Concerning Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements relate to, among other things, the financing transactions described herein, future results, operations, outlooks, plans, goals, reputation, cash flows and liquidity and other events which have not yet occurred. Forward-looking statements reflect management's current expectations and are subject to risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from the future results, performance or achievements expressed or implied in those forward-looking statements. Factors that could affect our results include, among others, those discussed under the caption "Risk Factors" in our most recent annual report on Form 10-K, as well as our other filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained by visiting the  Investor Relations page of our website at www.carnivalcorp.com/investors/ or the SEC's website at www.sec.gov. Undue reliance should not be placed on the forward-looking statements in this release, which are based on information available to us on the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Carnival Corporation & plc

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

By Reuters

September 30, 20258:05 PM UTCUpdated ago

The logo for Occidental Petroleum is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 30, 2019. REUTERS/Brendan McDermid Purchase Licensing Rights, opens new tab

CompaniesSept 30 (Reuters) - Berkshire Hathaway is in talks to buy Occidental Petroleum's

(OXY.N), opens new tab petrochemical unit for about $10 billion, the Wall Street Journal reported on Tuesday citing people familiar with the matter.

Sign up here.

Reporting by Katha Kalia in Bengaluru; Editing by Tasim Zahid

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

MALMÖ, Sweden, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”) announced today that it has issued SEK denominated senior secured floating rate bonds in a total amount of SEK 1,700 million (the “Nordic Bonds”), entered into a new sustainability-linked SEK 750 million super senior revolving credit facility agreement and intends to complete its repurchase of certain U.S. Notes (as defined below).

Marie-José David, Oatly’s CFO, commented, “These transactions represent yet another step forward in our company’s transformation journey. They strengthen our financial foundation by reducing our total outstanding debt, lowering costs related to the remaining outstanding debt, improving the terms of our capital structure, as well as reducing the dilution impact of our convertible notes. We have done all this while not raising additional financing and our business plan remaining fully funded.”

The proceeds from the Nordic Bonds will initially fund into an escrow account and are intended to be released to the Company on or around October 3, 2025, subject to customary conditions. The new senior revolving credit facility is intended to become effective thereafter, subject to prepayment in full of the group’s existing $130 million term loan B credit facility (the “TLB”) and customary conditions. As previously communicated, the Company intends to use the net proceeds from the Nordic Bonds to prepay the TLB in full, to repurchase and cancel certain of its U.S. Notes as further described below and to pay related transaction costs.

The proceeds from the Nordic Bonds will also be used to complete the transactions contemplated by the Convertible Note Repurchase Agreements (the “Repurchase Agreements”) which the Company entered into on September 9, 2025, with certain accredited investors (the “Selling Noteholders”) that are holders of the Company’s 9.25% Convertible Senior PIK Notes due 2028 (CUSIP No. 67421J AC2) (the “U.S. Notes”). The transactions contemplated by the Repurchase Agreements will result in U.S. Notes sold by the Selling Noteholders being cancelled and no longer outstanding, and are expected to close on or around October 3, 2025, following release of the Nordic Bonds proceeds from escrow and prepayment of the TLB in full and subject to customary conditions.

Additional information regarding the foregoing transactions may be found in a Form 6-K that will be filed with the U.S. Securities and Exchange Commission.

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. There can be no assurances that the transactions will be completed as described herein or at all.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding our financial outlook for 2025, profitability improvement, profitable growth in 2025, long-term growth strategy, expected capital expenditures, anticipated returns on our investments, anticipated supply chain performance, anticipated impact of our improvement plans, anticipated impact of our decision to discontinue construction of certain production facilities, plans to achieve profitable growth and anticipated cost savings and efficiencies as well as statements that include the words “expect”, “intend”, “plan”, “believe”, “project”, “forecast”, “estimate”, “may”, “should”, “anticipate”, “will”, “aim”, “potential”, “continue”, “is/are likely to” and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: our ability to consummate the transactions discussed herein on terms favorable to us or at all, our history of losses and how we may be unable to achieve or sustain profitability, including due to elevated inflation and increased costs for transportation, energy and materials; how our future business, financial condition and results of operations may be adversely affected by reduced or limited availability of oats and other raw materials and ingredients, which meet our quality standards, that our limited number of suppliers are able to sell us; how a failure to obtain necessary capital when needed on acceptable terms, or at all, may force us to delay, limit, reduce or terminate our product manufacturing and development and other operations; those concerning our cash and cash equivalents maintained at financial institutions, often in balances that exceed federally insured limits; any damage or disruption at our production facilities, which manufacture the primary components of all our products; harm to our brand or reputation due to real or perceived quality, food safety, nutrition or sustainability issues with our products, which could have an adverse effect on our business, reputation, financial condition and results of operations; food safety and food-borne illness incidents or other safety concerns that have led to product recalls and how such events may in the future materially adversely affect our business, financial condition and results of operations by exposing us to lawsuits or regulatory enforcement actions, increasing our operating costs and reducing demand for our product offerings; how a failure by our suppliers of raw materials or co-manufacturers to comply with food safety, environmental or other laws and regulations, or with the specifications and requirements of our products, may disrupt our supply of products and adversely affect our business; we may not be able to compete successfully in our highly competitive markets; risks from consolidation of customers or the loss of a significant customer; a reduction in sales of our oatmilk varieties, which contribute a significant portion of our revenue, would have an adverse effect on our business, financial condition and results of operations; relying heavily on our co-manufacturing partners; our strategic partnerships with co-manufacturers may not be successful, which could adversely affect our operations and manufacturing strategy; failure by our logistics providers to deliver our products on time, or at all, could result in lost sales; that we may not successfully ramp up operations at any of our facilities, or these facilities may not operate in accordance with our expectations; a failure to effectively expand our processing, manufacturing and production capacity through existing facilities, or a failure to find acceptable co-manufacturing or co-manufacturing partners to help us expand, as we continue to grow and scale our business to a steady operating level; failure to develop and maintain our brand; failure to develop or introduce new products or successfully improve existing products may adversely affect our ability to continue to grow; a failure to cost-effectively acquire new customers and consumers or retain our existing customers and consumers, or a failure to derive revenue from our existing customers consistent with our historical performance; consumer preferences for our products are difficult to predict and may change, and, if we are unable to respond quickly to new trends, our business may be adversely affected; a failure to manage our future growth effectively; impairment charges for long-lived assets and other exit costs in connection with our production facilities, and how we may need to recognize further costs in the future; sustainability risks (including environmental, climate change, uncertainty about future related mandatory disclosure requirements, and broader corporate social responsibility matters), which may materially adversely affect our business as a result of lawsuits, regulatory investigations and enforcement actions, complaints concerning our disclosures, impacts on our operations and supply chain (particularly in connection with the physical impacts of climate change), and impacts on our brand and reputation; reliance on information technology systems and how any inadequacy, failure or interruption of, or cybersecurity incidents affecting, those systems may harm our reputation and ability to effectively operate our business; how cybersecurity incidents or other technology disruptions could negatively impact our business and our relationships with customers; risks associated with how our customers generally are not obligated to continue purchasing products from us; difficulties as we expand our operations into countries in which we have no prior operating experience; risks associated with the international nature of our business; the successful execution of the strategic review of the Company’s Greater China operations, the outcome of the strategic review and the market reaction thereto; how our operations in China could expose us to substantial business, regulatory, political, financial and economic risks; our strategic reset in Asia may not be successful; if we fail to comply with trade compliance and economic sanctions laws and regulations of the United States, the EU and other applicable international jurisdictions, it could materially adversely affect our reputation and results of operations; packaging costs are volatile and may rise significantly; how fluctuations in our results of operations may impact, and may have a disproportionate effect on, our overall financial condition and results of operations; how litigation or legal proceedings could expose us to significant liabilities or costs and have a negative impact on our reputation or business; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all; failure to retain our senior management or to attract, train and retain qualified employees; if we cannot maintain our company culture or focus on our mission as we grow, our success and our business and competitive position may be harmed; our insurance may not provide adequate levels of coverage against claims or we may be unable to find insurance with sufficient coverage at a reasonable cost; disruptions in the worldwide economy; macroeconomic conditions, including rising inflation, interest rates and supply chain constraints; global conflicts, other effects of ongoing wars and conflicts, and increasing geopolitical tensions and changes to international trade policies, treaties and tariffs, including as a result of the emergence of a trade war; the risk that legal claims, government investigations or other regulatory enforcement actions could subject us to civil and criminal penalties; how our operations are subject to U.S., EU, China and other laws and regulations, and there is no assurance that we will be in compliance with all regulations; changes in existing laws or regulations, or the adoption of new laws or regulations, may increase our costs and otherwise adversely affect our business, financial condition and results of operations; how we are subject to stringent environmental regulation and potentially subject to environmental litigation, proceedings and investigations; failure to protect our intellectual property, enforce or defend our intellectual property and other proprietary rights adequately, which may impact our commercial success; if we are unable to remediate material weaknesses, or if other material weaknesses are identified, we may not be able to report our financial results accurately, prevent fraud or file our periodic reports as a public company in a timely manner; how our largest shareholder has significant influence over us, including significant influence over decisions that require the approval of shareholders; and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 13, 2025 and our other filings with the SEC as such factors may be updated from time to time. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Oatly disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025.

GIG HARBOR, Wash., Sept. 30, 2025 (GLOBE NEWSWIRE) -- California Water Service Group (NYSE: CWT) subsidiary Washington Water Service (Washington Water) has filed a request with the Washington Utilities and Transportation Commission (UTC) to increase water rates to recover $14.9 million in costs it has incurred to fund the improvement and maintenance of its local water systems as well as increased expenses over the last two years.

Some of the major investments made in Washington Water’s service areas include:

Installing 1,000 feet of water main in the Minterbrook system; 700 feet of main in Sunshine Acres; 2,500 feet of main in the Ranch Acres Shores system; 2,000 feet of main in Cedar Grove; 1,000 feet of main in Evergreen Shores; and 7,000 feet of main in the Southwood system to improve reliability and fire protection, and reduce potential leaks.Installing treatment facilities to remove lead and copper in the Heritage Row system, arsenic in the Quistorff system, and iron and manganese in the Southwood system.Conducting booster pump station upgrades in the Rosario, Cedar Crest, Artondale, Southwood, Olympic Mall, and Driftwood Valley systems.Deploying Supervisory Control and Data Acquisition remote system monitoring in the Sunshine Acres, Rosario, Mirrormont, Palmer Lake, and Southwood systems.Installing a new booster pumping facility to increase reliability and capacity in the Lost Creek zone of the Southwood system. Additionally, the proposed water rate increase accounts for costs incurred due to higher operating expenses, such as cost increases in materials and equipment; depreciation expense due to the addition of newly installed facilities; and increased labor costs. It also accounts for costs incurred for testing for the presence of per- and polyfluoroalkyl substances (PFAS) in accordance with new federal regulations, and other efforts related to PFAS regulatory compliance.

“We take our responsibility to provide our Washington Water customers safe, clean, reliable water at affordable rates seriously, and the upgrades we have made over the past two years are critical to continuing to deliver on this commitment,” said Marty Kropelnicki, Chairman and CEO. “At the same time, we work diligently to control expenses and keep water service affordable in the face of increasingly stringent federal and state water quality standards and rising costs.”

If approved as filed, new rates could become effective as early as Nov. 15, 2025.

About California Water Service Group

California Water Service Group (NYSE: CWT) is the largest regulated water utility operating exclusively in the western United States. It provides high-quality, reliable water and/or wastewater services to more than 2.1 million people in California, Hawaii, New Mexico, Washington, and Texas through its regulated subsidiaries, California Water Service, Hawaii Water Service, New Mexico Water Service, and Washington Water Service, and its utility holding company, Texas Water Service. 

Group’s purpose is to enhance the quality of life for customers, communities, employees, and stockholders. To do so, it invests responsibly in water and wastewater infrastructure, sustainability initiatives, and community well-being. The company’s nearly 1,300 employees live by a set of strong core values and share a commitment to protecting the planet, caring for people, and operating with the utmost integrity. The company has been named one of “America’s Most Responsible Companies” and one of the “World’s Most Trustworthy Companies” by Newsweek, a USA Top Workplace, and a Great Place to Work®. More information is available at www.calwatergroup.com.

This news release contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 ("PSLRA"). The forward-looking statements are intended to qualify under provisions of the federal securities laws for "safe harbor" treatment established by the PSLRA. Forward-looking statements in this news release are based on currently available information, expectations, estimates, assumptions and projections, and our management's beliefs, assumptions, judgments and expectations about us, the water utility industry and general economic conditions. These statements are not statements of historical fact. When used in our documents, statements that are not historical in nature, including words like will, would, expects, intends, plans, believes, may, could, estimates, assumes, anticipates, projects, progress, predicts, hopes, targets, forecasts, should, seeks or variations of these words or similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this news release include, but are not limited to, statements describing Washington Water's request to increase water rates and, if approved, the potential timing for such rates to become effective. Forward-looking statements are not guarantees of future performance. They are based on numerous assumptions that we believe are reasonable, but they are open to a wide range of uncertainties and business risks. Consequently, actual results or outcomes may vary materially from what is contained in a forward-looking statement. Factors that may cause actual results or outcomes to be different than those expected or anticipated include, but are not limited to those described under the section entitled "Risk Factors" and elsewhere in our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q and our other Securities and Exchange Commission filings. In light of these risks, uncertainties and assumptions, investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. We are not under any obligation, and we expressly disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact
Yvonne Kingman
[email protected]
310-257-1434

September 30, 2025 16:15 ET

 | Source:

American Assets Trust, Inc.

SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its third quarter 2025 earnings in a press release to be issued after the market closes on Tuesday, October 28, 2025.

Senior management will hold a conference call for its third quarter 2025 earnings on Wednesday, October 29, 2025 at 8:00 a.m. Pacific Time (“PT”).

To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust, Inc. Conference Call.

A live on-demand audio webcast of the conference call will be available on the “Investor Relations” section of the Company’s website at www.americanassetstrust.com. A replay webcast will be available on the Company’s website approximately one hour after the conclusion of the conference call.

About American Assets Trust, Inc.

American Assets Trust, Inc. is a full service, vertically integrated and self-administered real estate investment trust (“REIT”), headquartered in San Diego, California. The company has over 55 years of experience in acquiring, improving, developing and managing premier office, retail, and residential properties throughout the United States in some of the nation’s most dynamic, high-barrier-to-entry markets primarily in Southern California, Northern California, Washington, Oregon, Texas and Hawaii. The company's office portfolio comprises approximately 4.3 million rentable square feet, and its retail portfolio comprises approximately 2.4 million rentable square feet. In addition, the company owns one mixed-use property (including approximately 94,000 rentable square feet of retail space and a 369-room all-suite hotel) and 2,302 multifamily units. In 2011, the company was formed to succeed to the real estate business of American Assets, Inc., a privately held corporation founded in 1967 and, as such, has significant experience, long-standing relationships and extensive knowledge of its core markets, submarkets and asset classes. For additional information, please visit www.americanassetstrust.com.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the federal securities laws, which are based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” or “potential” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: adverse economic or real estate developments in our markets; defaults on, early terminations of or non-renewal of leases by tenants, including significant tenants; decreased rental rates or increased vacancy rates; our failure to generate sufficient cash flows to service our outstanding indebtedness; fluctuations in interest rates and increased operating costs; our failure to obtain necessary outside financing; our inability to develop or redevelop our properties due to market conditions; investment returns from our developed properties may be less than anticipated; general economic conditions, including the impact of tariffs and other trade restrictions; financial market fluctuations; risks that affect the general office, retail, multifamily and mixed-use environment; the competitive environment in which we operate; system failures or security incidents through cyberattacks; the impact of epidemics, pandemics, or other outbreaks of illness, disease or virus and the actions taken by government authorities and others related thereto, including the ability of our company, our properties and our tenants to operate; difficulties in identifying properties to acquire and completing acquisitions; our failure to successfully operate acquired properties and operations; risks related to joint venture arrangements; potential litigation; difficulties in completing dispositions; conflicts of interests with our officers or directors; lack or insufficient amounts of insurance; environmental uncertainties and risks related to adverse weather conditions and natural disasters; other factors affecting the real estate industry generally; limitations imposed on our business and our ability to satisfy complex rules in order for American Assets Trust, Inc. to continue to qualify as a REIT, for U.S. federal income tax purposes; and changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates and taxation of REITs. While forward-looking statements reflect the company's good faith beliefs, assumptions and expectations, they are not guarantees of future performance. For a further discussion of these and other factors that could cause the company's future results to differ materially from any forward-looking statements, see the section entitled “Risk Factors” in the company's most recent annual report on Form 10-K, and other risks described in documents subsequently filed by the company from time to time with the Securities and Exchange Commission. The company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.

Source: American Assets Trust, Inc.

Investor Contact:
American Assets Trust
Robert F. Barton
Executive Vice President and Chief Financial Officer
858-350-2607

, /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its third quarter 2025 on Thursday, October 30, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. 

The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You can access the conference call by dialing 1-800-836-8184 within the U.S. or +1 646-357-8785 outside the U.S. a few minutes before 2:00 PM PT and referencing Conference ID #95263.

Envista's earnings press release, the webcast slides, and other related presentation materials will be posted to the "Investors" section of Envista's website before the conference call and will remain available following the call.

ABOUT ENVISTA HOLDINGS CORPORATION

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.

FOR FURTHER INFORMATION
Jim Gustafson
Vice President, Investor Relations
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
Telephone: (714) 817-7000
[email protected] 

SOURCE Envista Holdings Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

, /PRNewswire/ -- Simon Griffiths, President and Chief Executive Officer of Camden National Corporation (NASDAQ: CAC; the "Company"), announced today that the board of directors of the Company declared a quarterly dividend of $0.42 per share. This quarterly payout results in an annualized dividend yield of 4.34% based on the September 29, 2025 closing price of the Company's common stock at $38.72 per share as reported by NASDAQ. The dividend is payable on October 31, 2025, to shareholders of record at the close of business on October 15, 2025.

About Camden National Corporation

Camden National Corporation (NASDAQ: CAC) is Northern New England's largest publicly traded bank holding company, with approximately $6.9 billion in assets. Founded in 1875, Camden National Bank has 72 banking centers in Maine and New Hampshire and is a full-service community bank offering the latest digital banking, complemented by award-winning, personalized service. Additional information is available at CamdenNational.bank. Member FDIC. Equal Housing Lender.

Comprehensive wealth management, investment, and financial planning services are delivered by Camden National Wealth Management.

SOURCE Camden National Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Ad hoc announcement pursuant to Art. 53 LR

Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring1   1.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines2,3Remibrutinib also in clinical development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa, expanding Novartis Immunology portfolio
Basel, September 30, 2025 – Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Rhapsido is a pill taken twice daily and does not require injections or lab monitoring. It is the first FDA-approved Bruton’s tyrosine kinase inhibitor (BTKi) for CSU. Rhapsido helps to inhibit the release of histamine and other proinflammatory mediators by targeting BTK, offering a unique approach to CSU treatment.1  

“CSU is a serious disease that can cause debilitating symptoms and unpredictable flares. It’s difficult to diagnose and manage,” said Mark Lebwohl, MD, Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai and member of the steering committee for the remibrutinib REMIX Phase III clinical trial program. “Remibrutinib represents a new way of treating CSU. By blocking the activity of BTK, remibrutinib stops a key pathway of the immune response in CSU. This is an exciting new option that has the potential to help a broad range of patients get fast relief.”

CSU is a mast cell-driven condition thought to be caused by immune dysregulation. In people with CSU, the immune system can become activated through allergic (IgE) or autoimmune (IgG) pathways.4 This causes certain immune cells—mast cells and basophils—to activate the BTK protein. While not fully understood, it is believed that once activated, BTK leads to the release of histamine and other proinflammatory mediators that may cause the red, swollen, and itchy hives commonly seen in CSU.5,6

CSU symptoms are unpredictable, recurring for six weeks or more without an identified cause.7 Diagnosis can take up to 24 months.8 Many CSU patients say their symptoms negatively impact their sleep, work, and mental health.9,10,11 Antihistamines are the first-line treatment, but over half of patients still have symptoms, even at higher doses.2 Injectable treatments exist for those who don't respond to antihistamines, yet fewer than 20% of eligible patients receive them.12

“The approval of remibrutinib is an important development in CSU care. It quickly reduces symptoms, offering patients control of the hives and itching that they experience on a daily basis,” said Giselle Mosnaim, MD, MS, an Allergist and Immunologist from Endeavor Health, Clinical Associate Professor at the University of Chicago Pritzker School of Medicine and REMIX trial investigator. “This is significant because it expands beyond existing injectable treatments and gives patients an oral option that can easily be incorporated into their daily lives.”

“Many CSU patients feel misunderstood and settle for treatments that don’t fully meet their needs,” said Lynda Mitchell, CEO of Allergy & Asthma Network. “We support new treatment options that empower patients to choose what works best for them. This convenient new oral therapy offers a promising new way to manage CSU and potentially improve daily life for those living with this challenging condition.”

Clinical data supporting approval
The FDA approval of Rhapsido in CSU is based on results from the Phase III REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) clinical trials in patients who remained symptomatic on second-generation H1 antihistamines. Rhapsido demonstrated superiority in change from baseline versus placebo in itch (ISS7), hives (HSS7), and weekly urticaria activity (UAS7) at Week 12.13 Significantly more patients treated with Rhapsido versus placebo achieved well-controlled disease (UAS7≤6) as early as Week 2 and at Week 12, and about one-third of patients achieved complete absence of itch and hives at Week 12.13 Rhapsido has a demonstrated safety profile that requires no lab monitoring.13 The most common adverse events (incidence ≥3%) were nasal congestion, sore throat, and runny nose (nasopharyngitis), bleeding, headache, nausea, and abdominal pain.13

Novartis has completed regulatory submissions for Rhapsido for the treatment of CSU across many countries, including in the European Union, Japan, and China, with priority review granted in China. 

Transforming care in Immunology
“This approval of Rhapsido as the first and only BTK inhibitor in CSU is an important milestone in our journey to reshape care for overlooked immune-related conditions and offer more patients the potential to find fast relief,” said Victor Bultó, President, US, Novartis. “Building on our legacy in advancing the treatment of allergic, dermatologic, and rheumatologic conditions, we are deeply committed to further investing in innovative, patient-focused therapies across immunology.”

Discovered and developed by Novartis to target the BTK pathway as a driver of inflammation, remibrutinib is being investigated in ongoing clinical trials across a variety of immune-related conditions, including chronic inducible urticaria (CIndU), hidradenitis suppurativa (HS), and food allergy.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

Rhapsido® (remibrutinib) Prescribing Information. Novartis Pharmaceuticals Corp. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66:317-330. doi:10.1111/j.1398-9995.2010.02496.xThe World Bank. Population, total. Accessed June 2025. https://data.worldbank.org/indicator/SP.POP.TOTLKolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819-1831. doi:10.1016/j.jaci.2022.04.010Kolkhir, P., Giménez-Arnau, A.M., Kulthanan, K. et al. Urticaria. Nat Rev Dis Primers. 8, 61 (2022). https://doi.org/10.1038/s41572-022-00389-zMendes-Bastos P, Brasileiro A, Kolkhir P, et al. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy. 2022;77(8):2355-2366.Maurer M, Costa C, Gimenez Arnau A, et al. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Clin Exp Allergy. 2020;50:1166-1175. doi: 10.1111/cea.13716Friedman A, Kwatra SG, Yosipovitch G. A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria. Dermatol Ther (Heidelb). 2024;14(6):1371-1387. doi: 10.1007/s13555-024-01173-5Mendelson M, Bernstein J, Gabriel S, et al. Patient-reported impact of chronic urticaria compared with psoriasis in the United States. J Dermatolog Treat. 2017; 28(3):229-236. doi:10.1080/09546634.2016.1227421 Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005-2016. doi:10.1111/all.13209Balp M-M, Krupsky K, Balkaran BL, et al. Oral presentation at: European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023; June 9–11, 2023; Hamburg, Germany.Maurer M, Raap U, Staubach P, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy.2019; 49: 655–662. https://doi.org/10.1111/cea.13309Metz M, Giménez-Arnau A, Hide M, et al. Long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria in the Phase 3 REMIX-1 and REMIX-2 studies. Presented as a late oral abstract session on clinical trials at EAACI 2024; May 31-June 3, 2024; Valencia, Spain.
Novartis Media Relations
E-mail: [email protected]       Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: [email protected]   9/25        UPR        FA-11459252